|
- BioNTech: Advancing science to help transform cancer and infectious . . .
BioNTech develops mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies in oncology, and vaccines against infectious diseases
- BioNTech - Wikipedia
BioNTech SE ( biːˈɒntɛk bee-ON-tek; or baɪˈɒntɛk bye-ON-tek[3] short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases
- Welcome to our investor page | BioNTech
Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases
- BioNTech (BNTX) Is Up 7. 9% After Raising 2025 Revenue Guidance on . . .
In late November, BioNTech raised its full-year 2025 revenue guidance, recognizing US$700 million from its collaboration with Bristol-Myers Squibb, while reporting a net loss for the quarter due
- BioNTech | About
BioNTech is a global biopharmaceutical company pioneering novel investigative therapies for cancer and infectious diseases We are committed to transforming how cancer is treated
- BioNTech’s Strategic Acquisition Reaches Critical Shareholder . . .
BioNTech shares have demonstrated a cautious pattern in response to the impending decision Following a 25 percent decline in value since the beginning of the year, compounded by recent pressure from Partner Pfizer’s share sales, investors are seeking clarity regarding the company’s strategic direction for the 2026 fiscal year
- BioNTech (BNTX) Q3 2025 Earnings Call Transcript - The Motley Fool
BioNTech's pipeline includes a three-wave strategy for Pumitamig, concurrently advancing foundational chemo combinations and novel ADC regimens to maximize long-term differentiation
- BioNTech Completes Acquisition of Biotheus | BioNTech
With the closing of the transaction, BioNTech will expand its capabilities to develop, manufacture and commercialize novel BNT327 combinations and next-generation bispecific antibodies
|
|
|